An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa

References

• Saunte DML, Jemec GBE. Hidradenitis Suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019–2032. doi: 10.1001/jama.2017.16691
   PubMed Web of Science ®Google Scholar
• Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. doi: 10.1038/s41572-020-0149-1
   PubMed Web of Science ®Google Scholar
• Ingram JR, Jenkins-Jones S, Knipe DW, et al. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917–924. doi: 10.1111/bjd.16101
   PubMed Web of Science ®Google Scholar
• Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760–764. doi: 10.1001/jamadermatol.2017.0201
   PubMed Web of Science ®Google Scholar
• Thorlacius L, Cohen AD, Gislason GH, et al. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52–57. doi: 10.1016/j.jid.2017.09.008
   PubMed Web of Science ®Google Scholar
• Vangipuram R, Vaidya T, Jandarov R, et al. Factors contributing to depression and chronic pain in patients with hidradenitis suppurativa: results from a single-center retrospective review. Dermatology. 2016;232(6):692–695. doi: 10.1159/000453259
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Damiani G, Orenstein LAV, et al. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61. doi: 10.1111/jdv.16677
   PubMed Web of Science ®Google Scholar
• Miller IM, McAndrew RJ, Hamzavi HI. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):7–16. doi: 10.1016/j.det.2015.08.002
   PubMed Web of Science ®Google Scholar
• Sampogna F, Fania L, Mazzanti C, et al. The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression. J Eur Acad Dermatol Venereol. 2020;34(8):e386–e388. doi: 10.1111/jdv.16290
   PubMed Web of Science ®Google Scholar
• Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152(4):429–434. doi: 10.1001/jamadermatol.2015.6264
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–644. doi: 10.1111/jdv.12966
   PubMed Web of Science ®Google Scholar
• van Straalen, KR, Tzellos T, Guillem P, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. J Am Acad Dermatol. 2021;85(2):369–378. doi: 10.1016/j.jaad.2020.12.089
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434. doi: 10.1056/NEJMoa1504370
   PubMed Web of Science ®Google Scholar
• Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001–1009. doi: 10.1001/jamasurg.2021.3655
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69.e2. doi: 10.1016/j.jaad.2018.05.040
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761. doi: 10.1016/S0140-6736(23)00022-3
   PubMed Web of Science ®Google Scholar
• Chu CB, Yang CC, Hsueh YY, et al. Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2023;189(6):719–729. doi: 10.1093/bjd/ljad273
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hänni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790–798. doi: 10.1016/j.jaad.2010.07.010
   PubMed Web of Science ®Google Scholar
• Navrazhina K, Garcet S, Frew JW, et al. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. J Am Acad Dermatol. 2022;86(2):322–330. doi: 10.1016/j.jaad.2021.07.035
   PubMed Web of Science ®Google Scholar
• Kanni T, Tzanetakou V, Savva A, et al. Compartmentalized cytokine responses in hidradenitis suppurativa. PLOS ONE. 2015;10(6):e0130522. doi: 10.1371/journal.pone.0130522
   PubMed Web of Science ®Google Scholar
• Navrazhina K, Garcet S, Gonzalez J, et al. In-depth analysis of the hidradenitis suppurativa serum proteome identifies distinct inflammatory subtypes. J Invest Dermatol. 2021;141(9):2197–2207. doi: 10.1016/j.jid.2021.02.742
   PubMed Web of Science ®Google Scholar
• Stergianou D, Micha S, Tzanetakou V, et al. Immune classification of hidradenitis suppurativa: modulation by secukinumab. J Invest Dermatol. 2023;143(12):2518–2520.e3. doi: 10.1016/j.jid.2023.04.028
   PubMed Web of Science ®Google Scholar
• Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17: Treg cell axis which is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137(11):2389–2395. doi: 10.1016/j.jid.2017.05.033
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906. doi: 10.1016/j.immuni.2019.03.021
   PubMed Web of Science ®Google Scholar
• Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136(9):1768–1780. doi: 10.1016/j.jid.2016.04.036
   PubMed Web of Science ®Google Scholar
• Campanati A, Orciani M, Sorgentoni G, et al. Pathogenetic characteristics of mesenchymal stem cells in hidradenitis suppurativa. JAMA Dermatol. 2018;154(10):1184–1190. doi: 10.1001/jamadermatol.2018.2516
   PubMed Web of Science ®Google Scholar
• Secukinumab (AIN457). 2023. Novartis Pharmaceuticals Corporation. U.S. Food and Drug Administration Report. (Revised on 2023 October). Available from: https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
   Google Scholar
• Cosentyx (secukinumab). 2023. EMA Public Assessment Report. (Last updated on 2023 AUG 30). Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
   Google Scholar
• Bruin G, Loesche C, Nyirady J, et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol. 2017;57(7):876–885. doi: 10.1002/jcph.876
   PubMed Web of Science ®Google Scholar
• Koenders MI, van den Berg WB. Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Devel Ther. 2016;10:2069–2080. doi: 10.2147/DDDT.S105263
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434–1442. doi: 10.1111/bjd.13270
   PubMed Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611. doi: 10.1111/bjd.17822
   PubMed Web of Science ®Google Scholar
• Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524–1526. doi: 10.1016/j.jaad.2020.02.005
   PubMed Web of Science ®Google Scholar
• Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441–e442. doi: 10.1111/jdv.17178
   PubMed Web of Science ®Google Scholar
• Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, et al. Short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study. Dermatol Ther (Heidelb). 2023;13(4):1029–1038. doi: 10.1007/s13555-023-00906-2
   PubMed Web of Science ®Google Scholar
• Zouboulis C, Passeron T, Mendes-Bastos P, et al. Efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa previously treated with biologic therapy: Week 16 results from the SUNSHINE and SUNRISE trials. Abstract presented in American Academy of Dermatology (AAD) annual meeting, p. 17–21 March, New Orleans, USA.
   Google Scholar
• Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279–1288. doi: 10.1001/jamadermatol.2021.2905
   PubMed Web of Science ®Google Scholar
• Zouboulis C, Gottlieb A, Forman S, et al. Bimekizumab efficacy across weight and BMI based subgroups in patients with moderate to severe hidradenitis suppurativa: 48‑week pooled results from the randomised, double-blind, placebo‑controlled, multicentre BE HEARD I and II phase 3 trials. 32nd EADV; 11–14 October 2023; Berlin. European Academy of Dermatology and Venereology; 2023. p. FC03.2.
   Google Scholar
• Frew JW, Navrazhina K, Sullivan-Whalen M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. Br J Dermatol. 2021;184(2):350–352. doi: 10.1111/bjd.19478
   PubMed Web of Science ®Google Scholar
• Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341–1348. doi: 10.1016/j.jaad.2020.05.007
   PubMed Web of Science ®Google Scholar
• Frew JW, Grand D, Navrazhina K, et al. Assessing the responsiveness of sonographic biomarkers to brodalumab therapy in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2021;35(12):e884–e887. doi: 10.1111/jdv.17536
   PubMed Web of Science ®Google Scholar
• Schuch A, Fischer T, Boehner A, et al. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17a antibody secukinumab. Acta Derm Venereol. 2018;98(1):151–152. doi: 10.2340/00015555-2794
   PubMed Web of Science ®Google Scholar
• Jørgensen AR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;2018:1–3. doi: 10.1155/2018/8685136
   Google Scholar
• Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182–185. doi: 10.1111/bjd.15769
   PubMed Web of Science ®Google Scholar
• Marasca C, Megna M, Balato A, et al. Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep. 2019;5(2):184–187. doi: 10.1016/j.jdcr.2018.12.002
   PubMedGoogle Scholar
• Villegas-Romero I, Collantes-Rodríguez C, Valenzuela-Ubiña S, et al. Moderate to severe hidradenitis suppurativa successfully treated with secukinumab. Actas Dermo-sifiliogr. 2020;111(8):696–698. doi: 10.1016/j.ad.2019.07.007
   PubMed Web of Science ®Google Scholar
• Reguiaï Z, Fougerousse AC, Maccari F, et al. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750–e751. doi: 10.1111/jdv.16605
   PubMed Web of Science ®Google Scholar
• Nikolakis G, Kreibich K, Vaiopoulos A, et al. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Res. 2021;10:381. doi: 10.12688/f1000research.52100.2
   PubMedGoogle Scholar
• Unal Enginar A, Gundogdu M. Successful treatment of hidradenitis suppurativa with secukinumab in a patient with ankylosing spondylitis and familial mediterranean fever. Mod Rheumatol Case Rep. 2022;6(1):19–21. doi: 10.1093/mrcr/rxab008
   PubMedGoogle Scholar
• Melgosa Ramos FJ, García Ruiz R, Estébanez Corrales A, et al. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. 2023;37(4):e517–e519. doi: 10.1111/jdv.18685
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285. doi: 10.1186/s13075-017-1490-y
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-imterleukin-17A monoclonal antibody, in psoriatic arthritis: a randomized, double-blind, placebo-controlled, phase 3 (FUTURE 2) trial. Lancet. 2015;386(9999):1137–1146. doi: 10.1016/S0140-6736(15)61134-5
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J DermatolTreat. 2018;29(1):13–18. doi: 10.1080/09546634.2017.1329511
   Google Scholar
• van Straalen KR, Ma F, Tsou PS, et al. Single cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa. J Clin Invest. 2023; doi 10.172/JCI169225.
   Web of Science ®Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized controlled trial. JAMA Dermatol. 2016;152(1):52–59. doi: 10.1001/jamadermatol.2015.3903
   PubMed Web of Science ®Google Scholar
• Navrazhina K, Frew JW, Gilleaudeau P, et al. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol. 2021;147(6):2213–2224. doi: 10.1016/j.jaci.2020.12.651
   PubMed Web of Science ®Google Scholar